Telix Pharmaceuticals (ASX:TLX) developed and validated a generator technology to produce the lead-212 isotope for Targeted Alpha Therapy, completing its first production run, according to a Thursday statement.

The technology, created by Telix's IsoTherapeutics team, uses a sealed thorium-228 source, offering higher radioactivity, improved yield, and longer shelf life than the existing technology, overcoming lead-212 short half-life and production challenges, the statement said.

The automated generator produces up to 60 clinical doses per elution and can be scaled for broader production, the statement added.

Telix plans to expand this technology across its manufacturing and distribution networks, including the recently acquired RLS Radiopharmacies, the company said.

Shares of the company rose 1% in recent Friday trade.